Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Novavax ( NASDAQ: NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company declined 1.73% to $6.54 on Friday afternoon. The vaccine maker lost close ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump issued letters to 17 companies, ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

Vertiv (NYSE:VRT) has agreed to acquire the Great Lakes Data Racks & Cabinets family of companies for $200 million. Vicebio, ...